Subscribe To

Price Alert Latest News Economic Calendar News

SCNLF / Scancell makes strong progress with lead immunotherapy assets

Key highlights for biotech group Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s financial year ending April 30 included a positive data reading arising from SCIB1's Phase-1 trial for advanced melanoma and progress in the first phase of the Modi-1 clinical trial (ModiFY). Modi-1 is the first vaccine based on Scancell's Moditope platform, while the ModiFY study is a first-in-human clinical trial for patients with triple-negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. Read More

Demo Live Account See Partner Details

Content Topics

Scancell

Makes

Strong

Progress

With

Lead

Immunotherapy

Assets

Stock

SCNLF

Posted: Oct 31 2023, 04:48

Author Name: Proactive Investors

SCNLF News

By Proactive Investors
November 1, 2023

Scancell melanoma trial data chosen for poster presentation at SITC

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) told investors that it has been selected for a poster presentation of data from the first stage of its Pha

By Proactive Investors
October 31, 2023

Scancell makes strong progress with lead immunotherapy assets

Key highlights for biotech group Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s financial year ending April 30 included a positive data reading arising

By Proactive Investors
October 18, 2023

Scancell to speak at prestigious vaccine event

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), which is developing immunotherapies for cancer and infectious disease, said its chief executive and chie

By Proactive Investors
September 19, 2023

Scancell trial results back strong value prospects - broker

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s expectation-busting initial results from the phase II SCOPE trial in advanced melanoma backs Stifel's vi

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.